125 related articles for article (PubMed ID: 6542462)
21. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
Stahl GL; Bitterman H; Lefer AM
Thromb Res; 1989 Feb; 53(3):327-38. PubMed ID: 2718150
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of a novel thromboxane analog in lethal traumatic shock.
Lefer AM; Araki H; Smith JB; Nicolaou KC; Magolda RL
Prostaglandins Med; 1979 Sep; 3(3):139-46. PubMed ID: 552102
[TBL] [Abstract][Full Text] [Related]
23. Effect of cyclooxygenase and thromboxane synthetase inhibition on furosemide-stimulated plasma renin activity.
Datar S; McCauley FA; Wilson TW
Can J Physiol Pharmacol; 1987 Jan; 65(1):80-3. PubMed ID: 3105853
[TBL] [Abstract][Full Text] [Related]
24. Effects of adenosine, an adenosine-A1 antagonist, and their combination in splanchnic occlusion shock in rats.
Karasawa A; Rochester JA; Lefer AM
Circ Shock; 1992 Feb; 36(2):154-61. PubMed ID: 1582007
[TBL] [Abstract][Full Text] [Related]
25. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Hock CE; Phillips GR; Lefer AM
Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
[TBL] [Abstract][Full Text] [Related]
26. Involvement of brain thromboxane A in hypotension induced by haemorrhage in rats.
Yalcin M; Cavun S; Yilmaz MS; Cengiz F; Savci V
Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):960-7. PubMed ID: 16405453
[TBL] [Abstract][Full Text] [Related]
27. Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.
Aoki N; Lefer AM
Methods Find Exp Clin Pharmacol; 1988 Jul; 10(7):413-8. PubMed ID: 3419244
[TBL] [Abstract][Full Text] [Related]
28. The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia.
Wainwright CL; Parratt JR
Adv Myocardiol; 1985; 6():573-84. PubMed ID: 4039460
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock.
Squadrito F; Altavilla D; Zingarelli B; Ioculano MP; Campo GM; Calapai G; Saitta A; Urna G; Sardella A; Spignoli G
J Cardiovasc Pharmacol; 1992 Jan; 19(1):115-9. PubMed ID: 1375677
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
31. Cloricromene improves survival rate and peritoneal macrophage function in splanchnic artery occlusion shock in rats.
Sturniolo R; Squadrito F; Altavilla D; Trimarchi GR; Prosdocimi M; Caputi AP
Circ Shock; 1989 Jul; 28(3):267-77. PubMed ID: 2766481
[TBL] [Abstract][Full Text] [Related]
32. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of oligotide, a novel oligodeoxyribonucleotide, in murine traumatic shock.
Skurk C; Nuss C; Lefer AM
Shock; 1995 Jan; 3(1):13-20. PubMed ID: 7531603
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of CG-4203, a novel stable prostacyclin analog, in traumatic shock.
Bitterman H; Stahl GL; Lefer AM
Prostaglandins; 1988 Jan; 35(1):41-50. PubMed ID: 3287456
[TBL] [Abstract][Full Text] [Related]
35. Testing the "redirection hypothesis" of prostaglandin metabolism in the kidney.
Datar S; McCauley FA; Wilson TW
Prostaglandins; 1987 Feb; 33(2):275-85. PubMed ID: 3296006
[TBL] [Abstract][Full Text] [Related]
36. Sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate (U-63557A), a new, selective thromboxane synthase inhibitor: intravenous and oral pharmacokinetics in dogs and correlations with ex situ thromboxane B2 production.
Wynalda MA; Liggett WF; Fitzpatrick FA
Prostaglandins; 1983 Aug; 26(2):311-24. PubMed ID: 6685888
[TBL] [Abstract][Full Text] [Related]
37. Evidence for a role of platelet activating factor in hypovolemic shock in the rat.
Zingarelli B; Squadrito F; Bussolino F; Calapai G; Altavilla D; Ioculano M; Campo GM; Canale P; Caputi AP
J Lipid Mediat Cell Signal; 1994 Mar; 9(2):123-34. PubMed ID: 8012759
[TBL] [Abstract][Full Text] [Related]
38. Effects of a pyridine derivative thromboxane synthetase inhibitor and its inactive isomer in endotoxic shock in the rat.
Anderegg K; Anzeveno P; Cook JA; Halushka PV; McCarthy J; Wagner E; Wise WC
Br J Pharmacol; 1983 Apr; 78(4):725-32. PubMed ID: 6687819
[TBL] [Abstract][Full Text] [Related]
39. Protective effects of a platelet activating factor (PAF) antagonist and its combined treatment with prostaglandin (PG) E1 in traumatic shock.
Terashita Z; Stahl GL; Lefer AM
J Cardiovasc Pharmacol; 1988; 12(5):505-11. PubMed ID: 2468048
[TBL] [Abstract][Full Text] [Related]
40. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
